MO-PIERIANDX
PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx clinical genomic report in combination with its cancer profiling assays. Under the agreement, PierianDx will integrate the Pillar Biosciences PiVAT® bioinformatics pipeline in the PierianDx environment to provide users with an accelerated implementation, including assay-specific variant filters, to produce best-in-class clinical genomics reports and enable a complete sample-to-answer solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201014005056/en/
Laboratories worldwide use Pillar Biosciences’ assays to detect pivotal genetic variants for cancer and other diseases. Pillar Biosciences’ targeted panels utilize a proprietary enrichment chemistry, SLIMamp®, that enables rapid, automated amplification of overlapping amplicons in a single tube using minimal sample inputs. Pillar Biosciences’ complementary bioinformatics pipeline, PiVAT® , is optimized for efficiency, reducing reflex testing and enabling low-frequency variant calling for every type of variant while consuming limited computing resources. PierianDx provides the Clinical Genomics Workspace™, which consists of intuitive software and a robust clinical Knowledgebase that transforms variant information into a highly-structured and comprehensive physician-ready report.
Streamlining NGS along with clinical genomic interpretation and reporting, especially for sophisticated panels, remains time-consuming and challenging. By packaging the Pillar Biosciences panels with the PierianDx report, the result will be an out-of-the-box clinical genomic report that is optimized for each assay. Furthermore, the solution will be available to customers globally through secure, and in the case of European regions, Global Data Protection Regulation (GDPR)-compliant, cloud instances. As a result, laboratories and healthcare organizations worldwide will have a highly reliable method for providing these tests to enable precision diagnostics and treatments for their patients.
“The assays from Pillar Biosciences provide robust detection for all variant types in a simplified workflow,” states Gang Song, PhD, CEO of Pillar Biosciences. “By optimizing variant filters and integrating with the PiVAT pipeline, PierianDx is streamlining interpretation and reporting, which adds substantial value for our customers.”
Rakesh Nagarajan, MD, PhD and Founder and Chief Technical and Visionary Officer of PierianDx, adds, “We are thrilled to provide this support for the Pillar Biosciences assays. As the market shifts to more sensitive assays in the LDT space and leading assay manufacturers seek in vitro diagnostic (IVD) approval, we are committed to addressing challenges that arise from even greater complexity in the interpretation and reporting process.”
About PierianDx
Founded in 2014 out of Washington University in St. Louis, PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Its industry-leading clinical genomics technologies, CAP and CLIA accredited laboratory, IVD-ready knowledgebase and reporting solution, and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx drives the adoption of genomics in clinical care and accelerates the fight against somatic cancer and hereditary germline diseases. www.pieriandx.com .
About Pillar Biosciences
Pillar Biosciences is a clinical cancer diagnostics company based in Boston, Massachusetts and Shanghai, China. Our automatable variant detection technologies deliver robust results with rapid turnaround times through streamlined NGS workflows. Our SLIMamp® – and PiVAT® -based products help high-throughput reference laboratories and clinical oncology laboratories make precision medicine practical by boosting their diagnostic productivity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005056/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hamad International Airport's Senior Operations Manager appointed as CEO of Ancona International Airport14.10.2025 09:00:00 CEST | Press release
Ancona International Airport (“AIA”), a Njord Partners portfolio company, is pleased to announce the appointment of Giorgio Buffa as its new Chief Executive Officer, effective 13 October 2025. Giorgio Buffa joins Ancona from Doha’s Hamad International Airport, where he was the Senior Operations Manager. He brings over 20 years of dedicated experience in the airport and airline industries, having spent his entire career in aviation. He is recognised for driving operational excellence and pioneering sustainable development at Hamad International Airport, which has, for multiple years, been named the "World's Best Airport" by Skytrax, setting new standards in the airport sector. For the past nine years, he has been instrumental in overseeing key operational functions and successfully navigated the COVID-19 period as well as major events such as the FIFA World Cup. Formerly a pilot with Alitalia and Air One, Giorgio has held various senior leadership roles in airport operations, including
PPG introduces PPG MIX‘N’SHAKE automated stirring technology for body shops14.10.2025 08:30:00 CEST | Press release
System improves productivity, reduces waste, enhances color accuracy PPG (NYSE: PPG) today announced the introduction of PPG MIX‘N’SHAKE™ automated stirring technology designed to eliminate traditional manual stirring methods in the automotive refinish industry. The system, which is available globally, improves paint mix consistency, reduces consumable waste and saves time for painters and body shops. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013065453/en/ PPG MIX’N’SHAKE™ automated stirring technology replaces manual stirring processes to ensure a homogenized paint mix, complete color accuracy, and a better workplace. The PPG Mix‘n’Shake system will debut at the EQUIP AUTO trade show in Paris taking place Oct. 14-18. PPG will also showcase its PPG LINQ™ digital ecosystem, which is a finalist for the prestigious EQUIP AUTO Innovation Award. Because the PPG Mix‘n’Shake system eliminates manual stirring, it ensures con
Glesys to Acquire Verne’s Managed Private Cloud Operations and Two Data Centers in Finland14.10.2025 08:00:00 CEST | Press release
Verne, the leading provider of low-carbon high-performance data centers across the Nordics, has today announced that Glesys, a leading Nordic provider of cloud and IaaS services, will acquire Verne’s managed private cloud operations in Finland, including data center facilities in Pori and Tampere. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006898290/en/ Pori Data Center Tunnel Corridor The agreement reflects both companies’ strategic priorities: for Glesys, it represents an important step in expanding its cloud and IaaS services, strengthening its position as a market leader in the Nordics and enhancing its capacity to deliver secure, energy-efficient and scalable solutions in the region. For Verne, it supports a sharpened focus on delivering low-carbon, high-performance colocation for AI and enterprise workloads, including its expansion plans in Mäntsälä, announced earlier this year. Glesys and Verne will continue to
Avanzanite Expands Italian Operations with General Manager Appointment14.10.2025 07:30:00 CEST | Press release
Giovanni Galliano joins Avanzanite having led 12 orphan medicine launches in Italy and overseen operations with more than €100 million in annual revenue. Avanzanite initiates engagement with the Italian rare blood disorder community who include the largest number of thalassemia patients in Europe. Avanzanite’s Q3 2025 revenues are 20% higher than Q2 2025, marking the strongest quarter to date. Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, announced today the appointment of Giovanni Galliano as General Manager for Italy. As the seventh executive leadership hire in 2025, this appointment further strengthens Avanzanite’s “Champions League” team of now more than 60 pharma professionals, while expanding operations into the European Union's third-largest economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013986565/en/ Giovanni Galliano, th
The Estée Lauder Companies Opens Global Fragrance Atelier in Paris, Accelerating Next-Generation Innovation in Perfume Artistry14.10.2025 07:00:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL), under the High Patronage of Mr. Emmanuel Macron, President of the French Republic,today announced the opening of its Fragrance Atelier within its new La Maison des Parfums on Rue Volney in Paris. This newly established global innovation hub is fully dedicated to world-class fragrance expertise, advanced technologies and cutting-edge capabilities, and will accelerate the company’s strategic ambitions in luxury and prestige fragrances. Rooted in the legacy of Mrs. Estée Lauder’s pioneering vision and her lifelong passion for fragrance, the Atelier’s opening marks a significant milestone in the company’s longstanding commitment to fragrance excellence and craftsmanship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013447078/en/ The Exterior of La Maison des Parfums “It is with great pride and excitement that we open our Fragrance Atelier in Paris,” said Stéphane de La Faverie, Pre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom